(Q38254337)

1 September 2017

1 reference

title

The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon (English)

1 reference

1 September 2017

1 reference

Archana Chatterjee

1

1 reference

1 September 2017

26 September 2014

1 reference

Expert Review of Vaccines

1 September 2017

1 reference

1 September 2017

13

1 reference

1 September 2017

1279-1290

1 reference

1 September 2017

11

1 reference

Global burden of human papillomavirus and related diseases.

1 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Reducing HPV-associated cancer globally.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

International incidence rates of invasive cervical cancer after introduction of cytological screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

HPV and cervical cancer: screening or vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Human papillomavirus: science and technologies for the elimination of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Epidemiology of Genital Human Papillomavirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Epidemiology of recurrent respiratory papillomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

The health and economic burden of genital warts in a set of private health plans in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999--2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Development and implementation of papillomavirus prophylactic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Provinces weighing HPV vaccination of boys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Modeling preventative strategies against human papillomavirus-related disease in developed countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Prevalence of cervical human papillomavirus (HPV) infection in Vanuatu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Control of HPV infection and related cancer through vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

The road ahead for cervical cancer prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

HPV vaccines: what remains to be done? Interview by Lauren Constable.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

The improbable plunge. What facts refute reasons to expect that the effectiveness of HPV vaccination programs to prevent cervical cancer could be low?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

The India HPV-vaccine suspension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.963561

10.1586/14760584.2014.963561

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25256262